The study of Hemay007 in patients with rheumatoid arthritis
Tianjin Hemay Pharmaceutical Co.,Ltd started a new clinical trial of A Multicenter, Randomized, Double-blind Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Hemay007 in Patients With Moderate to Severe Rheumatoid Arthritis.
The study start date is March 26, 2021.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05247216.